Zone 2 - Center 420°F 460°F 215°C 235°C Zone 3 - Front 430°F 470°F 220°C 240°C Nozzle 440°F 480°F 225°C 250°C Melt & Mold Temperatures English (°F) Metric (°C) Comments Melt Temperature 440°F 480°F 225°C 250°C Wipe down mold surface after each production run.Mold Temperature 125°F 200°F 50°C 90°C Notes These guidelines are based on lab results, and their values may not reflect actual processes using different machinery.

However, in this case, designers had reduced the thickness of the part wall significantly to achieve a relative weight saving of 90 percent.

La vigencia de la firma electrónica en el documento, al igual que la integridad y autenticidad del mismo, deben ser verificados en www.conservador.cl, donde estará disponible por 90 días contados desde la fecha de su emisión.

They are constructed from layers of 0°/90° woven E-glass fiber reinforcements combined with a proprietary resin system in a continuous pultrusion manufacturing process.

Product ID FIBER-LINE® Coating Base Fiber Break Strength Yield Geometry Nominal Diameter Notes K1000 1x3 (HT) FIBER-LINE® Wearcoat™ Kevlar 125 LBs (55 KGs) 3930 FT/LB (2639 M/KG) Round/Flat .762 mm Highly twisted cord lubricated for easy under armor ripping K400 1x3 FIBER-LINE® Wearcoat™ Kevlar 65 LBs (29 KGs) 10989 FT/LB (7384 M/KG) Round/Flat .435 mm Lubricated for fast & easy ripping K1500 1x3 FIBER-LINE® Wearcoat™ Kevlar 200 LBs (91 KGs) 2500 FT/LB (1679 M/KG) Round/Flat .905 mm Lubricated for fast & easy ripping P3000 (HT) FIBER-LINE® Repelcoat™ PET Polyester 60 LBs (27 KGs) 3935 FT/LB (2645 M/KG) Round .695 mm Water repellency coating V1420T FIBER-LINE® Blockcoat™ VectranTM 90 LBs (40 KGs) 9010 FT/LB (6050 M/KG) Round/Flat .456 mm Vectran utilized to eliminate outgassing.

Key Features • High strength to weight ratio • Good creep resistance • High abrasion resistance • Excellent flex fatigue properties • Minimal moisture absorption • Excellent chemical resistance Disadvantages • Vectran® suffers from UV degradation, which causes strength loss and discoloration • Hair-like filaments tend to fray FIBER-LINE® PROCESS FOR VECTRAN® LIQUID CRYSTAL POLYMER • Coating • Twisting • Extrusion • Pultrusion • Precision Winding FIBER-LINE® VECTRAN® PRODUCTS • Strength Members • Ripcords • Belt & Hose Reinforcement Yarn • Industrial Fabric Yarn • Synthetic Wire Rope Abrasion Resistance Yarn on Yarn Abrasion Ultraviolet (UV) Resistance Flame Resistance Chemical Resistance (Acid) Chemical Resistance (Alkali) Chemical Resistance (Organic Solvent) P P X P P P P Property UOM Value Breaking Tenacity g/d 23.0 Specific Gravity Ratio 1.40 Elongation @ Break % 3.8 Tensile Modulus g/d 600 Moisture Regain* %

Hanna consolidate • Cultures clash – commodity wins • Dependent on income derived from commodity joint ventures The First 6 Years • Globally organized along three strategic platforms • Non-core equity investment dispositions • Talent upgrades, discipline instilled throughout organization • New CEO hired to transform POL into specialty business �18 of 20 officers new • Implemented four pillar strategy • Nearly 50% of The Second 6 Years History of PolyOne – A Transformation • Focused on increasing volume, not profits • Heavily tied to cyclical markets 2000 2006 2012 The FormationThe Formation The TransformationThe Transformation The New PolyOneThe New PolyOne organization • Demonstrated ability to deliver • Nearly 50% of business operating income derived from Specialty Platform* • Specialty assets acquired *Pro forma for ColorMatrix acquisition Page 8 30% 50% 70% 90% $10 $12 $14 $16 $18 PolyOnePolyOne Stock Price S&P 500 (relative performance) Strategy and Execution Drive Results | | | | -50% -30% -10% 10% 30% $0 $2 $4 $6 $8 $10 2006 2007 2008 2009 2010 2011 2012 Page 9 Four Pillar Strategy The World’s Premier Provider of Specialized Polymer Materials, Services & Solutions Page 10 60% 80% 100% % o f O p e ra ti n g I n co m e * Old PolyOne Transformation 2012 Target “What We Said” Mix Shift Highlights Specialty Transformation Ahead of Schedule *Operating Income excludes Corporate Charges ** Pro Forma for the acquisition of ColorMatrix and divestiture of SunBelt 2% 34% 42% 50% >50% 0% 20% 40% 2005 2008 2011 2011** 2012 % o f O p e ra ti n g I n co m e * JV's PP&S Distribution Specialty Specialty OI $5M $46M $89M $117M “What We Said” Page 11 2007 2012 Target 2011 “Where we were” “What we said” “Where we are” 1) Operating Income % Specialty 3.2% 10% - 12% 8.9% PP&S 6.1% 8% - 10% 7.2% Pro forma ColorMatrix Proof of Performance Distribution 3.0% 4% - 5% 5.6% 2) Specialty Platform sss% of Operating Income 20% >50% 50% 3) Specialty Vitality Index 21% 35% - 40% 49% 4) ROIC* (pre-tax) 11% >15% 16% 5) Sales outside the US 37% >40% 40% *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 12 2011 Pro forma ColorMatrix 2015 Target “Where we are” “Where we expect to be” 1) Operating Income % Specialty 8.9% PP&S 7.2% 12 – 16% 9 – 12% Elevating our Expectations and Yours PP&S 7.2% Distribution 5.6% 2) Specialty Platform % of Operating Income 50% 3) ROIC* (after-tax) 10% 4) Adjusted Annual EPS Growth 3 yr CAGR = 71% 9 – 12% 6 – 7.5% 65 – 75% 15% Double Digit Expansion *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 13 • Four pillar strategy, coupled with our ability to execute is driving results • Strong leadership team driving growth & executing • Innovation and services provide differentiation and How do we get there?

This literature shall NOT operate as permission, recommendation, or inducement to practice any patented invention without permission of the patent owner. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0 100 200 300 400 500 600 700 800 900 1000 Te ns ile S tr en gt h R et en ti on Hours Submerged Tensile Strength Retention Standard Nylon 6/6, 50% Long Glass Fiber Moisture Resistant Nylon 6/6, 50% Long Glass Fiber Specialty Nylon 6/12, 50% Long Glass Fiber

Avient products have not been designed for nor are they promoted or intended for use in: (a) medical devices categorized by either the United States Food and Drug Administration (FDA) or the International Standards Organization (ISO) as an “implant” device; or “Permanent” as defined under US Pharmacopoeia (USP) or ISO standards; or (b) active implantable medical devices as defined in EU Directive 90/385/EEC as amended; or (c) medical devices for “Long Term” use as defined in EU Directive 93/42/EEC as amended.

Avient products have not been designed for nor are they promoted or intended for use in: (a) medical devices categorized by either the United States Food and Drug Administration (FDA) or the International Standards Organization (ISO) as an “implant” device; or “Permanent” as defined under US Pharmacopoeia (USP) or ISO standards; or (b) active implantable medical devices as defined in EU Directive 90/385/EEC as amended; or (c) medical devices for “Long Term” use as defined in EU Directive 93/42/EEC as amended.